Prevalence of Postpartum Depression Among Patients of the CHUM GARE Clinic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
About this trial
Postpartum depression (PPD) is a frequent complication of the postnatal period but remains underdetected in routine clinical practice. This prospective clinical study, conducted at the high-risk pregnancy clinic of the CHUM, aims to estimate the prevalence of PPD among patients seen in postpartum follow-up. It also assesses the feasibility of implementing a standardized screening protocol that combines the administration of the Edinburgh Postnatal Depression Scale (EPDS) with a clinical decision-support algorithm to guide appropriate medical follow-up. The study also seeks to explore clinical characteristics associated with higher EPDS scores.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 years or more
Patient who gave birth within the last 4 weeks to 6 months
Ability to understand French or English and complete the EPDS questionnaire
Physically present at their post-partum visit at the clinic
Disqualifiers
Inability to comprehend and/or complete the EPDS
Declines participation or does not provide informed consent
Trial population
Patients of the high-risk pregnancy clinic (GARE - Grossesse à risque élevé) of the Centre hospitalier de l'Université de Montréal (CHUM) coming in for their post-partum visit with obstetrician
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Prevalence of postpartum depression in the study population
Proportion of patients with an EPDS score ≥13 at the 4 to 8-week postpartum visit. The Edimburgh Postnatal Depression Scale (EPDS) is a validated 10-item questionnaire designed to identify symptoms of depression in postnatal mothers. Each question asks about feelings and experiences over the past seven days, covering various emotional and psychological aspects related to perinatal mood. For each question, there are four possible responses, scored from 0 to 3, with higher numbers indicating more severe symptoms. The total EPDS score indicates the severity of potential depressive symptoms: a score of 13 or above often suggests a high risk of developing a depressive disorder.
Time frame
Baseline EPDS score (Day 0)Secondary outcomes
1
Orientation to a medical or psychosocial resource based on EPDS score and decision algorithm
Categorical outcome measuring the type of referral initiated following EPDS screening (e.g., pamphlet of information, primary care health services, psychiatrist, primary care physician, emergency department).
Time frame
Immediately after EPDS completion2
Repeat EPDS score at 2-week follow-up (for scores between 13 and 16 only)
EPDS score collected by telephone at 2 weeks for patients with a Day 0 score between 13 and 16. Outcome measured as the proportion of patients whose score remains ≥13. The Edimburgh Postnatal Depression Scale (EPDS) is a validated 10-item questionnaire designed to identify symptoms of depression in postnatal mothers.
Time frame
2 weeks after initial EPDS score3
Number of days before the first contact with referred service
Number of days between the initial referral (Day 0) and confirmed access to the referred service (by patient report).
Time frame
Assessed at two-week and, if needed, six-week follow-up calls4
Clinical and obstetrical factors associated with EPDS ≥13
Exploratory analysis to evaluate associations between an elevated EPDS score (≥13) and selected clinical variables, including age, level of education, lifestyle habits (smoking, alcohol or drug consumption), psychiatric, medical and obstetric history (including history of miscarriage), mode of delivery and method of perinatal analgesia, breastfeeding, iron-deficiency anemia or iron deficiency, obstetric, anesthetic, or neonatal complications, and skin-to-skin contact in the delivery room within the first 24 hours after birth.
Time frame
Chart review conducted following Day 0 visit and consentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov